US 11,851,707 B1
N-Myc-Interactor protein as a marker for chronic lung disease and uses thereof
Nirmal S. Sharma, Tampa, FL (US); Mudassir Banday, Tampa, FL (US); and Andreas Seyfang, Tampa, FL (US)
Assigned to University of South Florida, Tampa, FL (US)
Filed by University of South Florida, Tampa, FL (US)
Filed on Mar. 29, 2021, as Appl. No. 17/215,249.
Claims priority of provisional application 63/000,999, filed on Mar. 27, 2020.
Int. Cl. C12Q 1/6883 (2018.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61K 9/0043 (2013.01); A61K 9/51 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 4 Claims
 
1. A method of predicting and treating development of chronic lung allograft dysfunction (CLAD) in a patient in need thereof comprising:
obtaining a sample from the patient;
obtaining an expression level of N-myc-interactor (NMI) protein or gene in the sample;
comparing the expression level of the NMI protein or gene in the sample to a control;
wherein decreased expression of NMI protein or gene as compared to the control indicates the development of CLAD; and
administering to the patient a therapeutically effective amount of a therapeutic agent selected from the group consisting of antibiotics, neomacrolides, montelukast, pirfenidone, nintedanib, alemtuzamab, immunosuppressants, beneficial bacteria, and an NMI modulator composition if development of CLAD is indicated.